Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Strategies to optimize Phase III combination immunotherapy trials

Thomas Urban Marron • 16 Apr 2023
AACR 2023
General Antibodies Canakinumab

Thomas Urban Marron, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses issues in Phase III immunotherapy trials. Despite the success of immunotherapies such as TGF-β inhibitors and canakinumab, a novel IL-1β inhibitor, a number of therapies fail later stage trials due to the lack of suitable biomarkers. More thorough blood and biopsy analyses are needed to elucidate biomarkers. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Thomas Urban Marron

3:31
ctDNA linked to RFS in patients with HCC treated with neoadjuvant cemiplimab
Thomas Urban Marron • 16 Apr 2023
2:47
Blocking IL-4 activity with dupilumab in NSCLC
Thomas Urban Marron • 16 Apr 2023

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals